Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927105 · ClinicalTrials.gov registry record · Phase 2
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
A Phase 2 study of Peripheral T-Cell Lymphoma, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 3
- Study locations
NCT03927105 is a Phase 2 study of Peripheral T-Cell Lymphoma that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 4 participants, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03927105, a Phase 2 study of Peripheral T-Cell Lymphoma, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 3
- Study locations
Study Summary
A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG cabiralizumab
Study Locations (3)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Wisconsin
- Unviersity of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-04-25 |
| Est. Completion | 2023-07-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03927105
The ClinicalTrials.gov registry entry for NCT03927105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (96% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03927105 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Ohio, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03927105 about?
NCT03927105 is a clinical study titled "Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma". A multicenter trial evaluating the combination of nivolumab and the antagonistic CSF-1R monoclonal antibody cabiralizumab (BMS-986227) in patients with relapsed/refractory peripheral T cell lymphoma
What is the current status of trial NCT03927105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2019-04-25. Estimated completion is 2023-07-06.
What conditions does trial NCT03927105 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT03927105?
The interventions under investigation include: Nivolumab (DRUG), cabiralizumab (DRUG).
Who is sponsoring clinical trial NCT03927105?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03927105 being conducted?
This trial has 3 study locations across Michigan, Ohio, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.